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Abstract
Background—Despite widely-known negative effects of substance use disorders (SUD) on 
women, children, and society, knowledge about population-based prevalence and impact of SUD 
and SUD treatment during the perinatal period is limited.
Methods—Population-based data from 375,851 singleton deliveries in Massachusetts 2003–2007 
were drawn from a maternal-infant longitudinally-linked statewide dataset of vital statistics, 
hospital discharges (including emergency department (ED) visits), and SUD treatment records. 
Maternal SUD and SUD treatment were identified from one-year pre-conception through delivery. 
We determined (1) the prevalence of SUD and SUD treatment; (2) the association of SUD with 
women’s perinatal health service utilization, obstetric experiences, and birth outcomes; and (3) the 
association of SUD treatment with birth outcomes, using both bivariate and adjusted analyses.
Principal Findings—5.5% of Massachusetts’s deliveries between 2003–2007 occurred in 
mothers with SUD, but only 66% of them received SUD treatment pre-delivery. Women with SUD 
were poorer, less educated and had more health problems; utilized less prenatal care but more 
antenatal ED visits and hospitalizations, and had worse obstetric and birth outcomes. In adjusted 
analyses, SUD was associated with higher risk of prematurity (AOR 1.35, 95% CI 1.28–1.41) and 
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low birthweight (LBW) (AOR 1.73, 95%CI 1.64–1.82). Women receiving SUD treatment had 
lower odds of prematurity (AOR 0.61, 95%CI 0.55–0.68) and LBW (AOR 0.54, 95%CI 0.49–
0.61).
Conclusions—SUD treatment may improve perinatal outcomes among pregnant women with 
SUD, but many who need treatment don’t receive it. Longitudinally-linked existing public health 
and programmatic records provide opportunities for states to monitor SUD identification and 
treatment.
Keywords
substance use disorder; perinatal outcomes; perinatal health services utilization; SUD treatment; 
pregnancy; linked health data systems
INTRODUCTION
Substance use disorder (SUD) is a national public health problem among women of 
reproductive age, with potential consequences across generations. Substance use and abuse 
during the prenatal period is associated with increased risks for obstetric and medical 
complications (Behnke 2013; McDonald et al. 2007; Lester 2002; Wright and Walker 2002; 
Huestis and Choo 2000, Tuthill 2000; Ness et al. 1999), less prenatal care (Parlier 2014; 
Behnke 2013; Funkhouser et al. 1993), poor birth outcomes (Conradt 2013; Shankaran et al. 
2004; Huestis and Choo 2002; Lester 2002), and long-term health and behavioral problems 
in offspring (Behnke 2013; Lester 2010; Boucher et al. 2008; Miller-Loncar et al. 2005; 
Bada et al 2002; Ornoy et al 2001). Data from U.S. surveys indicate that approximately 
11.9% of women aged 15–44 report illicit drug use in the past month, and 23.7% report 
heavy or binge alcohol use, with fewer pregnant women using illicit drugs (5.3%) or heavy 
or binge drinking (2.8%) (National Survey on Drug Use and Health 2015; Pan and Yi, 
2013). The prevention of SUD is thus a public health priority with major implications for 
maternal and child health.
Despite the widely-known negative effects of SUD on women, children, and society, 
knowledge about the population-based prevalence and the impact of SUD during the 
perinatal period is limited and even less is known about the impact of SUD treatment on 
birth outcomes. Current substance abuse surveillance efforts depend on either: (1) medical 
record review for those who elect to enroll in studies, which does not provide generalizable 
or gender-specific data (Harrison and Sidebottom 2008; Fabris et al. 1998; Shankaran et al. 
1994; Funkhouser et al. 1993;); (2) biologic specimen testing (Behnke 2013), which is 
neither systematically administered during pregnancy nor universally at the time of delivery 
and depends on the timing of drug usage; or (3) national surveys, which only capture self-
reported medical/SUD conditions (Bada et al. 2002). Epidemiologic analyses often separate 
the mother-child dyad into unrelated individuals, thus limiting investigation of the impact of 
maternal SUD and SUD treatment on subsequent birth outcomes. Moreover, most state 
agencies can record frequencies of SUD treatment episodes, but can not examine patterns of 
treatment over time for individuals or assess the impact of treatment on women’s or infants’ 
health outcomes. The current study derives from a larger investigation of SUD among all 
Massachusetts women of childbearing age (15–49) in 2002–2008 (Bernstein et al., 2015). In 
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that study, 8.5% of women aged 15–49 were positive for SUD, and only 48% of those 
women received specialty SUD treatment. Women who received SUD services were less 
likely to relapse or utilize an emergency department in the year following treatment.
Our aims were to determine: (1) the prevalence of SUD and SUD treatment (overall and by 
maternal socio-demographic and substance use characteristics); (2) the association between 
SUD and women’s perinatal health service utilization, obstetric experiences, and birth 
outcomes (prematurity, low birthweight [LBW], fetal death, neonatal mortality, and post 
neonatal mortality); and (3) the association between SUD treatment and birth outcomes 
among deliveries to women with SUD, among Massachusetts women delivering singleton 
infants during the study period To our knowledge, this is the first study to directly investigate 
SUD identification and treatment among a population-based sample of reproductive-aged 
delivering women living in the U.S.
METHODS
Data Base
Institutional Review Boards of Boston University Medical Campus, Massachusetts General 
Hospital, and the Massachusetts Department of Public Health approved this study. We used 
three data sources to capture documentation of SUD among women of reproductive age in 
Massachusetts: (1) the Massachusetts Center for Health Information and Analysis (CHIA) 
case mix data, which provided SUD-related diagnostic codes from statewide hospital 
discharge records for all inpatient, observational stay, and emergency department discharges 
for women aged 15–49 years, including hospital-based inpatient substance abuse treatment 
services; (2) the Massachusetts Pregnancy to Early Life Longitudinal (PELL) data system, 
which links birth records to corresponding hospital delivery discharge records, and allows 
for extraction of evidence of SUDs from both maternal and infant records; and (3) the 
Massachusetts Bureau of Substance Abuse Services (BSAS) treatment dataset, which 
provides information about SUD treatment need and utilization in all publicly-funded free-
standing SUD specialty treatment programs in the state.
The linkage of these three datasets into singular limited data set, described elsewhere in 
detail (Bernstein et al, 2015), involved four broad steps: (1) aggregation of individual 
hospital utilization episodes (~6,000,000 records) into individual women-level records 
(~1,750,000); (2) linkage of these records to BSAS program records; (3) linkage to the 
PELL database of deliveries within the state; and (4) identification of women with recent 
pregnancies in the BSAS dataset.
Study Population
We restricted our study sample initially to women aged 15–49 years who received any 
inpatient (including deliveries), observational stay, emergency department, or SUD specialty 
treatment services in MA hospitals, or who participated in any BSAS SUD treatment 
programs between January 1, 2002 and December 31, 2008. We then further limited the 
study population to those women (N=316,839) who had a least one singleton delivery (live 
or stillborn) between January 1, 2003 and December 31, 2007. We then accounted for their 
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sequential singleton deliveries during the study time period, resulting in a total N=375,851 
of singleton deliveries, the unit of analysis for the current study. We further allowed for an 
additional year of data (2008) to ascertain infant mortality.
Measures
Substance use disorder—We classified women as having SUD based on: (1) birth 
certificate mention of a positive neonatal toxicology screen or fetal alcohol syndrome; (2) a 
BSAS treatment system admission record; or (3) specific International Classification of 
Diseases, 9th Edition, Clinical Modification (ICD-9-CM) codes identified by the Explicit 
Mention of Substance Abuse Need for Treatment in Women (EMSANT-W) algorithm, 
developed to identify women of reproductive age with SUD through their own diagnosed 
substance-related health conditions and those of their neonates. EMSANT-W is more fully 
described elsewhere (Derrington et al., 2015). Women who appeared in the dataset with no 
evidence of SUD from any source were classified as “non-SUD.”
Data on specific type of drug usage were obtained from hospital and emergency department 
records, and reports of “drug of choice” on admission to the Massachusetts BSAS treatment 
system dataset. We differentiated single substance use (alcohol only or drugs only) from 
“poly-use” (alcohol and drugs together), then by specific substances of interest: alcohol, 
crack/cocaine, heroin/opiates, cannabis, stimulants, and a grouped category consisting of 
sedatives, barbiturates, hypnotics, and anesthetics.
We used the PELL birth date to anchor all temporal measures (i.e., likely date of conception, 
timing of SUD identification and treatment) within the study period of one year 
preconception to date of delivery).
Treatment System Utilization—We characterized formal treatment of SUD treatment as 
(1) professional services received in a specialty treatment facility or hospital-based program; 
or (2) hospital-based services for detoxification. Specific evidence of treatment for SUD was 
based either on an admission to a SUD specialty treatment program monitored by BSAS 
(approximately 90% of all MA substance use treatment programs) or on an ICD-9-CM 
coding for an inpatient hospital-based detoxification admission. SUD treatment status was 
established independently for each delivery and defined based on the presence (yes/no) of 
any SUD treatment received during the time period between one year preconception through 
delivery. Pre-conception date was established based on birth certificate information..
BSAS data available for this study included dates of admission and discharge (treatment 
duration), reason for discharge, drug of choice, and treatment modality (i.e., detoxification, 
outpatient, residential or medication-assisted treatment such as methadone/buprenorphine, 
and transitional and other recovery support services).
Because multiple treatment strategies are often utilized concurrently, we grouped types of 
treatment into two categories of services: ‘acute only’ (e.g., admission for inpatient 
detoxification and stabilization, generally for five or fewer days), and ‘extensive treatment’ 
(all other modalities). For example, an admission for transitional services might precede a 
residential admission or outpatient counseling, but all of these modalities together were 
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defined as one extensive continuum of care and categorized together as ‘extensive treatment’ 
program services. [The impact of specific patterns of treatments and timing of treatment are 
beyond the scope of this initial paper.]
Perinatal Outcomes—Perinatal outcomes derived from the MA PELL data system 
included: (1) LBW (< 2500 grams); (2) prematurity (<37 weeks gestation); (3) fetal death 
(>20 weeks gestation or > 350 grams); (4) neonatal mortality (0–28 days); and (5) post-
neonatal mortality (29–365 days).
Maternal Obstetric Experiences (Outcomes)—Maternal obstetric experiences 
derived from PELL birth certificate and hospital discharge data included: (1) utilization of 
antenatal health services (prenatal care usage measured by the APNCU Index (Kotelchuck et 
al 1994), ED visits and hospital admissions); and (2) pregnancy-related morbidity (e.g., 
gestational diabetes, pregnancy induced hypertension) and delivery complications (e.g., 
premature rupture of membranes, fever, C-section).
Covariates—Socio-demographic covariates derived from PELL included maternal age, 
race/ethnicity, primary language, education level, marital status, parity, MA state region of 
residence, and health insurance coverage at birth. Specific chronic and acute medical 
conditions known to co-occur with SUD were identified through hospital ICD-9-CM 
diagnosis codes and birth certificate check-off boxes, including anemia, cardiac disease, 
diabetes, hepatitis B or C, hypertension, lupus erythematosis, pneumonia, renal disease, and 
seizure disorder.
Finally, we created summary variables for any residual chronic, non-SUD-related maternal 
health condition and for a psychiatric comorbidity history, which included ICD-9 codes for 
any mood disorders, psychoses, paranoid and anxiety states, personality disorders, 
adjustment disorders, PTSD, and stress reactions.
Analytic Approach
SAS v. 9.3 (Cary, NC) was used for all data linkage and analyses. We determined prevalence 
of SUD and SUD treatment, and then used chi-square analysis to evaluate associations of 
maternal and infant socio-demographic, birth, and health characteristics with SUD and SUD 
treatment. Because of the large study sample, virtually all the bivariate chi-square and all 
multivariate Wald chi-square relationships are statistically significant at p.<.001 and p values 
are not reported further in the text. We then used multivariate logistic regression analyses to 
estimate the association of SUD with infant outcomes including LBW, prematurity, fetal 
death, neonatal mortality, and post-neonatal infant mortality. The first model estimated 
unadjusted associations and the second model controlled for maternal age, race/ethnicity, 
primary language, education, marital status, parity, health insurance coverage, region of 
residence, chronic health conditions, psychiatric co-morbidity, adequacy of prenatal care, 
pregnancy-related conditions, delivery complications, and method of delivery. Finally, 
among women with identified SUD, we estimated the impact of SUD treatment on infant 
outcomes, using multivariable analyses controlling for the aforementioned covariates. In all 
multivariable models, we used generalized estimating equations (GEE) to account for the 
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non-independence of data from women who had more than one delivery during the time 
period.
RESULTS
SUD Prevalence
Among 375,851 MA singleton deliveries during 2003–2007, 5.5% or 20,707 occurred to 
women with SUD identified within one year of conception, during pregnancy, or at the time 
of delivery. Just over one-third (35.5%) were identified from BSAS records only; 49.9% 
from the EMSANT-W algorithm only; and 14.6% from both (data not shown).
Among the women with SUD, 15.9% used alcohol only; 34.2% used drugs only; and 49.9% 
used both alcohol and drugs. The primary types of substance used were alcohol (57.3%); 
crack/cocaine (38.9%); heroin, opiates, and/or methadone (39.5%); sedatives, barbiturates, 
hypnotics, and/or anesthetics (5.4%); and cannabis (37.2%). (Percentages add up to more 
than 100% due to multiple types of substances used). [Data not shown in tables.]
Characteristics of Women with SUD vs. Women without SUD
Women with SUD had more socio-demographic and health disadvantages than women 
without SUD (Table 1): they were younger (44.7% vs. 27.6% under 25), less educated 
(55.0% vs. 35.4% high school or less), and less likely to be married (55.8% vs. 70.6%) or 
have private health insurance (62.1% vs. 36.0%). They also had more pre-existing health 
conditions (65.1% vs. 44.1%) and co-morbid psychiatric diagnoses (53.1% vs. 13.1%).
Maternal Perinatal Experiences
Compared to women without SUD, women with SUD diagnoses were more likely to have 
experienced ED visits (38.3% vs. 21.9%) and hospitalizations (24.4% vs. 16.4%) during the 
antenatal period, but less preventive prenatal care (Table 2). Women with SUD had slightly 
more pregnancy-related morbidity and delivery complications. [Detailed maternal morbidity 
and complications data available from the authors]
SUD and Birth Outcomes
Deliveries to women with SUD had higher rates of LBW (11.1% vs. 5.5%), prematurity 
(13.1% vs. 8.7%), fetal death (0.6% vs. 0.4%), and neonatal mortality (0.66% vs. 0.36%) 
than deliveries to women without SUD (Table 3). After adjusting for covariates, deliveries to 
women with SUD were significantly more likely to be LBW (AOR=1.73, 95% CI: 1.64–
1.82) and premature (AOR=1.35, 95% CI: 1.28–1.41) than deliveries to women without 
SUD.
SUD Treatment Prevalence
Among the 20,707 deliveries to women with indicators of SUD, 66% (13,723) had evidence 
of receiving some mode of SUD treatment during the study period (Table 1). Of those 
receiving treatment, 7% had acute detox treatment only and 93% had more ‘extensive’ 
treatment. The vast majority 84% (11,495) of women who received treatment services 
obtained them through free-standing specialty programs that report to BSAS.
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SUD Treatment Access
Among all women with identified SUD need, those receiving SUD treatment compared to 
those without SUD treatment were more likely to be aged 30 or older (38.0% vs. 23.0%), 
have at least some college education (53.4% vs. 28.3%), be married (56.2% vs. 20.6%), have 
private insurance (49.8% vs. 14.6%), live in non-Boston metro regions of MA, and have 
fewer health (59.2% vs. 76.7%) or psychiatric (38.1% vs. 82.7%) conditions.
Treatment utilization also varied by the three broad substance groupings (data not shown). 
Cannabis use was associated with the lowest prevalence of treatment (29.9%) and 
barbiturate use was associated with the highest prevalence of treatment (49.4%), closely 
followed by heroin, opiates, and methadone (47.9%), alcohol (45.6%), and crack cocaine 
(42.0%).
SUD Treatment and Birth Outcomes
Among deliveries to women with identified SUD need (Table 4), we observed better birth 
outcomes for treated compared to untreated women. Treated women with SUD had lower 
rates of preterm (10.1% vs. 19.0%) and LBW (7.8% vs. 18.0%) births, as well as fetal, 
neonatal and post-neonatal mortality.
In multivariate analyses, SUD treatment was associated with reduced odds of LBW 
(AOR=0.54, 95% CI: 0.49–0.61), preterm birth (AOR=0.61, 95% CI: 0.55–0.68), and 
neonatal mortality (AOR=0.49, 95% CI: 0.31–0.74). Fetal deaths and post-neonatal 
mortality could not be analyzed in the fully adjusted model due to the small number of 
cases.
We conducted additional post-hoc comparisons by type of SUD treatment, but found no 
significant differences between acute only treatment and extensive treatment (Appendix A). 
We further stratified by broad maternal drug of choice groups: SUD treatment was 
associated with lower odds of LBW and prematurity for all drug groups, though the strength 
of the association for the alcohol only group was less than the others. Any treatment was 
associated with lower odds of LBW and prematurity among drug and poly-drug/alcohol-
using women, but not for the alcohol-only group.
DISCUSSION
We identified markers for substance use disorder during the period from one year prior to 
conception through the time of delivery among 5.5% of women with singleton deliveries 
(live births and fetal losses) in Massachusetts between 2003 and 2007. This prevalence and 
the differences we observed in socio-demographic characteristics, perinatal health and health 
services, and birth outcomes between deliveries to women with and without markers for 
SUD confirm prior reports from survey data and small sample trials within the current large 
population-based data set. What is especially new and noteworthy here is the association of 
treatment for SUD and lower risk of adverse birth outcomes on a population basis.
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SUD Prevalence Estimation
Our population-based prevalence of 5.5% deliveries to SUD-positive women in 
Massachusetts is consistent with national surveys from the same time period (SAMHSA, 
2007a; SAMHSA, 2007b; SAMHSA 2008). This estimate is lower than the 8.5% SUD 
prevalence for all MA women aged 15–49 years (Bernstein et al., 2015), and consistent with 
other studies reporting less substance use by women during pregnancy (Pan and Yi, 2013). 
Our findings may be more precise due to several strategies we used to identify women with 
SUD during the perinatal period. First, unlike previous analyses that have relied on a single 
data source, we identified women through birth records, BSAS participation records, and ED 
and hospitalization records. This linkage resulted in identification of women who may have 
opted not to disclose substance use in the medical setting an – important issue when 
substance use disclosure has legal (child protective/abuse) implications. Second, using the 
birth certificate data, with their gestational age markers, allowed us to assess the timing of 
when SUD identification and SUD treatment occurred in relation to the infant’s birth. Third, 
the inclusion of ED data, a frequent locus for treatment of SUD-associated health 
consequences, likely increased identification of women with SUD. Finally, the EMSANT-W 
identification algorithm provided us with a more comprehensive, gender-tailored 
identification of SUD using more precise criteria than previous reports (Derrington et al 
2014). We believe our population-based methodology identifies actual women with SUD 
rather than simply creating population estimates; and therefore allows for examination of the 
women’s subsequent health and health care, SUD treatment experiences, and their 
offspring’s health, which in turn can provide points of entry for public health program 
interventions.
SUD and Utilization of Perinatal Health Services
Our data show that SUD has a strong negative association with health care utilization during 
pregnancy. Roberts and Pies (2011) noted that women with SUD were inhibited by fear of 
being reported to Child Protective Services and by the burden of multiple socio-
demographic/health risk factors that are associated with SUD. SUD increases pregnant 
women’s health status burden, and increases their usage of episodic and emergent health 
services, and makes for more complex deliveries.
SUD and Birth Outcomes
SUD is a multigenerational, life course chronic disease. This study, like other epidemiologic 
studies (Burns and Mattick, 2007; Crome and Kumar, 2007; McDonald 2007; Escobar et al, 
2000), shows broad negative impacts of SUD on multiple birth outcomes, even after 
controlling for associated factors.
The current analysis did not reveal significant differences in maternal health, health services 
usage, or birth outcomes by drug type or by specific primary drug of choice. This finding 
may reflect the limitations of administrative data to identify principal substance use. 
Moreover, many substance users are poly-drug users and/or switch among substances, and 
thus could appear in many of the drug groupings in an administrative data system.
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SUD Treatment
The most important new findings from this study concern utilization of SUD treatment. In 
this study population, a third of women with SUD did not have evidence of any treatment 
during the period of one year pre-conception through delivery. Among those treated, 7% 
received no further SUD services beyond detox services, which also reflects an insufficient 
response to their treatment needs. The gap between women with unmet SUD treatment 
needs and receipt of services represents too many missed opportunities for active 
engagement into effective treatment, especially given that MA is one of seven states that 
prioritize pregnant women for access to SUD treatment. These treatment figures are, 
however, higher than the 48% of all MA women (15–49) with SUD who received treatment 
within one year prior to or one year following SUD identification (Bernstein et al., 2015). 
We also found important disparities in receipt of treatment; women who were younger, 
Black or Hispanic, less educated, lacking private insurance, unmarried and with health or 
psychiatric morbidities were all less likely to get SUD treatment. This suggests a need to 
increase access to services for the most vulnerable segments of women with SUD.
SUD Treatment and Birth Outcomes
In MA, SUD treatment was associated with substantially better birth outcomes, particularly 
for LBW and prematurity. Prior research has been limited to small samples and specific 
treatments; this finding is the first demonstration, to our knowledge, of a positive association 
with treatment on a population basis. In other prior related studies, Bernstein et al. (2014 & 
2015) showed that among all MA SUD women aged 15–49 years, SUD treatment was 
associated with decreased subsequent ED visits, injuries, and hospitalizations within one 
year of treatment.
Limitations
Our prevalence estimate of 5.5% of infants delivered to women with SUD is likely an 
underestimation. SUD diagnostic codes may have been warranted but not recorded, because 
substance use was not the focus of a medical encounter, or providers were reluctant to enter 
this information into a legal record, or women were reluctant to disclose use.
Our population-based analysis did not have the benefit of triangulation with clinical data that 
might have revealed more cases of SUD. We employed strong epidemiologic measures of 
SUD prevalence and treatment; but recognize the limitations in the use of any secondary 
databased SUD measurement algorithm, detecting false positives or false negatives is 
problematic.. Birth outcomes, such as gestational age, may also be incorrectly recorded. And 
methodologic limits to linkage of multiple data sets may also contribute to inaccurate 
estimates.
Differences in reproductive outcomes by SUD status or by SUD treatment exposure could be 
influenced by unidentified confounding risk factors that are differentially distributed across 
the SUD and SUD treatment groups. In particular, our data did not permit us to analyze birth 
outcomes by the quantity or severity of drug use either prior to treatment or post-treatment. 
Nor was the quantity and duration of tobacco use available for examination of their 
associations with pregnancy outcomes. And while the GEE outcome analyses statistically 
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account for the non-independence of data associated with women who had multiple 
deliveries, sequential deliveries itself was not examined as a separate independent risk factor
The definition of treatment was limited to services provided in professional medical or 
addiction treatment settings; and thus, Alcoholics Anonymous, Narcotics Anonymous or 
Driving While Intoxicated program participation was not included in this study. We also 
lacked treatment records from Veterans’ Administration or private facilities that did not 
contract with BSAS; nonetheless the sources we did have covered the vast majority of 
treatment options available for MA women with SUD.
Last, generalizability is limited by the age of the study data (2003–2007) and restriction to 
one state, since treatment access varies considerably over time and across regions of the 
country. However, our secondary data-based findings add to the existing prevalence 
estimates derived from surveys and samples restricted to women who received treatment, 
and allow, for the first time, a population-based analysis of the prevalence and possible 
impact of treatment.
Policy and Program Implications
Services for women with SUD who are or will become pregnant are inadequate even in 
Massachusetts, which provides a wide range of treatment modality options and venues. This 
study’s findings reinforce the need for women’s services, given the intergenerational 
importance of untreated SUD and the consequences for the health of both women and 
children. Creating linked, longitudinal data systems, with robust substance use measures, 
may help states improve their estimates of gender-specific SUD prevalence, treatment 
utilization, and health and health services consequences.
The life course effects of SUD can be modified, and pregnancy is often a very receptive 
period for behavioral change and intergenerational concerns. Infant outcomes may be 
improved among women with SUD who receive treatment. The study findings should give 
hope to women with SUD, their families, and clinicians, Clinicians have an important role to 
play in providing the study’s encouraging message to their clients. The study findings should 
also reinforce policy makers’ efforts to invest in treatment programs for women with SUD, 
which could lead to lower short- and long-term public expenditures and better population 
health outcomes.
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Appendix A. Association between substance use disorder treatments and 
preterm birth and low birthweight among singleton deliveries with 
identified SUD need, overall and by specific drug mentioned
Any Treatmenta Acute Treatmenta Extensive Treatmenta
Adjusted Odds of Preterm Birth
 Any Need (N=20,707) 0.61 (0.55–0.68) 0.59 (0.46–0.76) 0.62 (0.55–0.68)
 Alcohol Need Only (N=3,286) 0.95 (0.70–1.29) 0.99 (0.50–1.94) 0.94 (0.69–1.28)
 Drug Need Only (N=7,083) 0.59 (0.50–0.70) 0.51 (0.35–0.76) 0.59 (0.50–0.71)
 Alcohol and/or Drug Need (N=10,338) 0.58 (0.50–0.66) 0.61 (0.41–0.88) 0.58 (0.50–0.68)
 Alcohol (N=11,873) 0.71 (0.61–0.82) 0.69 (0.49–0.99) 0.71 (0.61–0.82)
 Crack/Cocaine (N=8,047) 0.54 (0.45–0.64) 0.48 (0.31–0.74) 0.55 (0.46–0.65)
 Heroin, Opiates, Methadone (N=8,183) 0.51 (0.43–0.61) 0.47 (0.32–0.69) 0.52 (0.44–0.62)
 Sedatives, Barbiturates, Hypnotics, Anesthetics 
(N=1,107)
0.65 (0.45–0.95) 0.29 (0.04–2.46) 0.71 (0.49–1.03)
 Cannabis (N=7,705) 0.59 (0.49–0.72) 0.54 (0.31–0.95) 0.60 (0.49–0.72)
Adjusted Odds of Low Birthweight
 Any Need (N=20,707) 0.55 (0.49–0.61) 0.48 (0.36–0.64) 0.55 (0.49–0.62)
 Alcohol Need Only (N=3,286) 0.81 (0.58–1.11) 0.55 (0.23–1.32) 0.82 (0.59–1.14)
 Drug Need Only (N=7,083) 0.56 (0.46–0.66) 0.49 (0.32–0.75) 0.55 (0.46–0.67)
 Alcohol and/or Drug Need (N=10,338) 0.50 (0.43–0.59) 0.46 (0.30–0.72) 0.51 (0.43–0.59)
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Any Treatmenta Acute Treatmenta Extensive Treatmenta
 Alcohol (N=11,873) 0.60 (0.51–0.70) 0.48 (0.31–0.73) 0.61 (0.52–0.71)
 Crack/Cocaine (N=8,047) 0.50 (0.42–0.59) 0.47 (0.30–0.76) 0.49 (0.41–0.59)
 Heroin, Opiates, Methadone (N=8,183) 0.46 (0.39–0.55) 0.44 (0.29–0.66) 0.47 (0.40–0.56)
 Sedatives, Barbiturates, Hypnotics, Anesthetics 
(N=1,107)
0.49 (0.34–0.70) 0.19 (0.02–1.48) 0.51 (0.35–0.74)
 Cannabis (N=7,705) 0.55 (0.45–0.67) 0.39 (0.19–0.78) 0.55 (0.45–0.67)
aVersus no treatment
Adjusted for maternal age, race/ethnicity, primary language, education, marital status, parity, health insurance coverage, 
region of residence, health conditions, psychiatric diagnosis, adequacy of prenatal care, pregnancy-related conditions, 
delivery complications, and method of delivery.
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SIGNIFICANCE
What is known
State-specific data regarding prevalence of substance abuse disorder (SUD) in the 
perinatal period are limited, as is research on effects of SUD treatment on delivery 
outcomes. States need these analyses to inform programming and policy decisions.
This study adds
The novel linked dataset utilized here provides population-level, state-specific 
information about SUD prevalence, perinatal health services utilization, birth 
complications, and SUD treatment prior to delivery. This study provides new information 
on negative maternal reproductive health outcomes associated with SUD, unmet SUD 
treatment need, and reduction in risk for prematurity and LBW after SUD treatment on a 
population-level..
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Table 3
Associations between the presence of maternal substance use disorder (SUD) and select birth outcomes 
(Singleton deliveries in MA from 2003–2007)
SUD
N (%)
Not SUD
N (%)
Model 1
OR (95% CI)
Model 2
AOR (95% CI)
Birth Outcome
 Preterm Birth 2,631 (13.1) 30,316 (8.7) 1.57 (1.51–1.64) 1.35 (1.28–1.41)
 Low Birthweight 2,292 (11.1) 19,614 (5.5) 2.13 (2.03–2.23) 1.73 (1.64–1.82)
 Fetal Death 127 (0.61) 1,576 (0.44) 1.38 (1.15–1.66) 1.24 (0.99–1.56)
 Neonatal Mortality 136 (0.66) 1,286 (0.36) 1.82 (1.52–2.17) 1.13 (0.93–1.38)
 Post neonatal Mortality 11 (0.05) 175 (0.05) 1.08 (0.59–1.98) 1.07 (0.38–1.34)
Model 1 is unadjusted; Model 2 is adjusted for maternal age, race/ethnicity, primary language, education, marital status, parity, health insurance 
coverage, region of residence, health conditions, psychiatric diagnosis, adequacy of prenatal care, pregnancy-related conditions, delivery 
complications, and method of delivery
All associated Wald chi-square comparisons are significant at p<.001
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Table 4
Associations between maternal substance use disorder (SUD) treatment and select birth outcomes among 
singleton deliveries with identified SUD need (n=20,707)
% Treatment % No Treatment Model 1OR (95% CI)
Model 2
AOR (95% CI)
Birth Outcome
 Preterm Birth 10.1 19.0 0.48 (0.44–0.52) 0.61 (0.55–0.68)
 Low Birthweight 7.8 18.0 0.37 (0.34–0.41) 0.54 (0.49–0.61)
 Fetal Death 0.5 0.8 0.66 (0.47–0.95) -
 Neonatal Mortality 0.4 1.2 0.34 (0.24–0.48) 0.49 (0.31–0.74)
 Post neonatal Mortality 0.03 0.1 0.29 (0.09–0.99) -
Model 1 is unadjusted; Model 2 is adjusted for maternal age, race/ethnicity, primary language, education, marital status, parity, health insurance 
coverage, region of residence, health conditions, psychiatric diagnosis, adequacy of prenatal care, pregnancy-related conditions, delivery 
complications, and method of delivery
All associated Wald chi-square comparison is significant at p<.001
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